Gabapentin Capsule
Product Images NDC 71335-2381

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2381). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Gabapentincapsules 01)

A mathematical formula for calculating creatinine clearance (CLCr), involving age, weight, serum creatinine, and a factor for female patients. The image presents the formula in a clear, typed format.*

FDA Label Image

Chemical Structure (Gabapentincapsules 02)

Chemical structure of gabapentin showing a cyclohexane ring with two substituents: an amino group (CH2NH2) and a carboxyl group (CH2CO2H).*

FDA Label Image

Figure 1 (Gabapentincapsules 03)

A line graph comparing mean pain scores over eight weeks between placebo and Gabapentin at 3600 mg/day. The X-axis represents time in weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The Y-axis shows mean pain scores from 0 to 10, with Gabapentin demonstrating a decrease over time compared to placebo.*

FDA Label Image

Figure 2 (Gabapentincapsules 04)

A line graph depicting mean pain scores over a span of seven weeks. The graph compares three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period, while the y-axis shows mean pain scores ranging from 0 to 10.*

FDA Label Image

Figure 3 (Gabapentincapsules 05)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares responder percentages across two studies for placebo (PBO) and gabapentin (GBP) at different doses (3600 mg, 1800 mg, and 2400 mg). The chart shows higher response rates for gabapentin groups versus placebo, with statistical significance indicated for some comparisons.*

FDA Label Image

Figure 4 (Gabapentincapsules 06)

A scatter plot chart showing the percentage difference versus daily dose (mg) for Gabapentin in three studies labeled Study a, Study b, and Study c. The x-axis represents daily doses of 600, 900, 1200, and 1800 mg, while the y-axis shows percentage difference values ranging from 2% to 22%. Different markers and labels represent data points from each study at varying doses.*

FDA Label Image

Label (Lbl713352381)

Label for Gabapentin Capsules, USP 400 mg, oral dosage form, containing 90 capsules. The product is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Zhejiang Yongtai Pharmaceutical Co., Ltd. The label includes the NDC number 71335-2381-1, storage instructions, and a warning about dizziness.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.